Lobular carcinoma in situ

@article{Afonso2008LobularCI,
  title={Lobular carcinoma in situ},
  author={Nelia M. Afonso and David L. Bouwman},
  journal={European Journal of Cancer Prevention},
  year={2008},
  volume={17},
  pages={312-316}
}
The diagnosis of lobular carcinoma in situ (LCIS) provokes considerable anxiety in patients owing to misconceptions about this diagnosis. Initially LCIS was considered a premalignant lesion, but it is now a marker of increased risk. The number of women diagnosed with LCIS has increased in recent years most likely owing to more rigorous breast cancer screening. Implications of this diagnosis and management options are discussed in this review. 
Lobular Carcinoma In Situ.
Molecular drivers of lobular carcinoma in situ
TLDR
This review focuses on the molecular drivers of lobular carcinoma, a more complete understanding of which may give perspective on which LCIS lesions progress, and which will not, thus having immense clinical implications.
Wide local extension and higher proliferation indices are characteristic features of symptomatic lobular neoplasias (LNs) and LNs with an early invasive component
TLDR
The aim of this study was to clarify the histopathological characteristics of clinically overt (symptomatic) LNs and early invasive LNs.
Significance of lobular intraepithelial neoplasia at margins of breast conservation specimens: a report of 38 cases and literature review
TLDR
The view that LIN seen at the margin may play a role in recurrence with BCT is supported, as LIN found at a margin on BCT showed a significant recurrent ipsilateral disease.
Lobular Neoplasia of the Breast
TLDR
The management of patients diagnosed to have lobular neoplasia is in evolution, with the increasing need for risk stratification and hence the necessity to identify this entity separately as either lobular carcinoma in‐situ and atypical lobular hyperplasia.
Clinicopathological Features and Prognosis of Lobular Carcinoma In Situ
TLDR
LCIS is often incidentally diagnosed without clinical symptoms, especially in women aged <50 years, and the prognosis of LCIS is excellent in cases that are surgically treated.
Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast--a review.
  • M. HussainG. Cunnick
  • Medicine
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • 2011
Idiopathic Granulomatous Mastitis with Incidental Lobular Carcinoma In Situ: A Case Report
TLDR
Radiologic findings of IGM can be suggestive of other possible causes and silent etiologies like the primary phase of breast cancer and LCIS should not be overlooked.
Multidisciplinary management of CDH1 germinal mutation and prophylactic management hereditary lobular breast cancer: A case report
The Evolution of Lobular Neoplasia
  • M. Lerwill
  • Medicine
    Advances in anatomic pathology
  • 2006
TLDR
Recent molecular studies, particularly those examining alterations in the E-cadherin gene, provide compelling evidence to support a role for lobular neoplasia as a direct precursor to invasive lobular carcinoma.
...
...

References

SHOWING 1-10 OF 54 REFERENCES
Lobular Carcinoma In Situ of the Female Breast
In a Danish nationwide prospective study of in situ carcinomas and atypical lesions of the breast, 88 women, comprising 69 patients with lobular carcinoma in situ (LCIS) and 19 patients with combined
Lobular carcinoma in situ of the breast: mammographic features.
TLDR
Calcifications were the most common reason for biopsy, although there were no distinctive mammographic features of LCIS.
Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988‐2001
TLDR
This data indicates that patients diagnosed with ductal carcinoma in situ or lobular carcinomas in situ are more likely to develop invasive breast cancer than those diagnosed with other types of cancer.
Lobular carcinoma in Situ of the breast: An approach to rational treatment
TLDR
Careful lifelong follow‐up seems to be the rational treatment for women whose breast biopsy shows LCIs and the development of invasive breast cancer (IBC) had no relation to the patient's age, nor could any correlation be drawn between the time periods which elapsed from the time of the diagnosis of the in situ cancer to theDevelopment of IBC.
Lobular Carcinoma In Situ of the Breast
  • E. Frykberg
  • Medicine
    Surgery, gynecology & obstetrics
  • 1987
TLDR
Although LCIS imparts as much as a 12‐fold increased risk of subsequent invasive breast carcinoma, its natural history suggests it is more of a marker of risk rather than a true premalignant lesion, which suggests that subsequent risk can be significantly reduced by tamoxifen.
Lobular carcinoma in situ: mammographic-pathologic correlation of results of needle-directed biopsy.
TLDR
It is concluded that isolated lobular carcinoma in situ has no characteristic mammographic features and is detected as an incidental finding at breast biopsy, with the mammographic abnormality predominantly reflecting a benign process.
Lobular carcinoma in situ of the breast(Long‐term followup
TLDR
The risk of subsequent development of infiltrating carcinoma in the breast with biopsyproven LCIS is shown to be substantially less than indicated by previous authors, which suggests that careful and prolonged followup may suffice for the woman whose breast biopsy contains lobular carcinomas in situ.
Mammary duct proliferation in the elderly. A histopathologic study
TLDR
It is concluded that occult infiltrating breast carcinoma, unlike occult prostatic carcinomas, is an infrequent lesion in the elderly and need not be viewed with alarm.
Lobular neoplasia (so‐called lobular carcinoma in situ) of the breast
TLDR
The ratio between the observed and expected numbers of patients developing carcinoma in the several possible combinations of these three factors which predispose to carcinoma is determined: in patients in whom all three predisposing factors were present the ratio of observed to expected risk of carcinoma was 13:8.
...
...